anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to three genes encoding short chain neurotoxin (refer to sn12,sn36 and sn160) obtained by Lapemis hardwick venom gland cDNA library construction and DNA sequencing. The three genes are modified and amplified by PCR methods, cloned into expression vector PETTRX. The expression host is BL21-DE3. The host is induced by IPTG. The three genes are highly effectively soluble fusion expressed. Short chain neurotoxin analgesia action test data showed that sn12,sn36 and sn160 can significantly improve pain threshold of mouse.
PURPOSE: A pharmaceutical composition containing colored potato peel extract or a fraction thereof is provided to suppress inflammatory factor activation and to prevent and treat inflammatory diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating inflammatory diseases contains colored potato peel extract or a fraction thereof as an active ingredient. The extract is prepared using water, low carbon number alcohol, or a mixture thereof. A method for preparing the fraction of the extract comprises: a step of cutting dry colored potato peel and extracting with water, low carbon number alcohol of C1-C4, or a mixture thereof; a step of concentrating the extract by decompression; and a step of suspending the extract in water and fractioning the extract with hexane, chloroform, ethyl acetate, and butanol. A functional food for preventing or treating inflammatory diseases contains the extract or a fraction thereof as an active ingredient. [Reference numerals] (AA) Jayoung peel CHCI_3 fr. (μg/ml); (BB) Jayoung peel BuOH fr. (μg/ml)
The invention discloses a traditional Chinese medicine composite for treating damp-heat pattern oesophageal carcinoma, which is prepared by the following crude drugs by weight part: A. 5-20 parts of rhubarb, 10-15 parts of realgar, 6-10 parts of radix curcumae, 3-5 parts of burging croton, 10-15 parts of pollen, 5-10 parts of fructus gardeniae powder; B. 15-20 parts of walnut meat, 8-10 parts of dried lacquer (powder), 15-20 parts of flowers carthami, 25-30 parts of radix angelicae, 15-20 parts of ligusticum wallichii, 15-20 parts of the root of red-rooted salvia, 15-20 parts of root of commonpeony, 25-30 parts of Chinese-date and 15-20 parts of rhizoma zingiberis. The A preparation is toxin-expelling cathartic which is taken for 1-2 times with 3-5g every time, and then B preparation is taken for 1-4 treating courses. The traditional Chinese medicine composite for treating damp-heat pattern oesophageal carcinoma has special medicine compatibility, skilful mediation and obvious effect,and has remarkable effect on treating early-stage and middle-stage damp-heat pattern oesophageal carcinoma, and has good treating effect, low treating cost and no side effect. The dryness of mouth, dry and yellow furred tongue, rapid pulse and nausea and vomiting feeling disappear and the lesion of the oesophageal carcinoma is for the better obviously by X-ray detection.
Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).
OBJECTIVE: To design a care protocol in Chronic Inflammatory Arthritis during the pre-conceptional period, pregnancy, postpartum and lactation. This protocol aims to be practical and applicable in consultations where patients with chronic inflammatory rheumatological diseases are treated, thus helping to better control these patients. Likewise, recommendations are offered on when patients could be consulted/referred to a specialized center by the physician.
METHODS: A multidisciplinary panel of expert physicians from different specialties identified the key points, analyzed the scientific evidence, and met to develop the care protocol.
RESULTS: The recommendations prepared have been divided into three blocks: rheumatology, gynecology and pediatrics. The first block has been divided into pre-pregnancy, pregnancy and postpartum visits.
CONCLUSIONS: This protocol tries to homogenize the follow-up of the patients from the moment of the gestational desire until the year of life of the infants. It is important to perform tests in patients of childbearing age and use drugs compatible with pregnancy. If appropriate, the patient should be referred to specialized units. Multidisciplinarity (rheumatology, gynecology and pediatrics) is essential to improve the control and monitoring of these patients and their offspring.
This is an open label, prospective single center study. Patients that are seen in our regional Tuberous Sclerosis Complex Clinic and have facial angiofibromas that would benefit from this cream and who wish to be involved in this study would be enrolled. We anticipate enrolling 12-15 patients the first year. Patients will have pictures of their facial angiofibromas taken immediately prior to entry into the study. They will then be prescribed 0.1% rapamune topical formulation to apply twice daily to their skin for the first two weeks and then once daily. If level is above 0, will re-check serum lipids, cbc, and repeat levels every three-four months and monitor the patient for symptoms. Patients will return at one month and three months to obtain serum rapamune levels along with pictures, then they will be seen intermittently throughout the first year with photographs of their face taken at the one month visit, 3 month visit, six month visit and twelve month visit. We will ask the parents about any side effects from the medication during the entire time patients are using the topical rapamune. We will monitor the facial lesions as well. We will assess for skin sensitivity, pain, erythema, or pruritus. If skin irritation results from the drug, then we will stop use of the drug. Parents will sign an informed consent allowing their child's picture to be taken and allowing us to summarize the data for publication at the end of this study.

This study will be the first study using a consistent formulation to make a 0.1% rapamune cream, and this will be performed under the direction of myself and Dr. Almoazen in the University of Tennessee Health Science Center(UTHSC) College of Pharmacy compounding laboratory. Only patients who are thought to be reliable for the follow up visits and to use the cream appropriately will be enrolled in the study. This study meets the FDA criteria for an Investigational New Drug(IND) exemption.

The adverse events noted in the package insert for rapamune cream are all based on systemic administration of the medication, primarily to adults with other diseases. In our clinical experience, with topical use there is no absorption and we have not noted any side effects.
Participants will receive oral dose of JNJ-70075200 on Day 1 in Cohort 1 under fasted condition. Part 3 will start after obtaining a formal regulatory/ethical approval.
The visual attentional deficits in delirium are poorly characterized. Studies have highlighted neuro-anatomical abnormalities in the visual processing stream but fail at quantifying these abnormalities at a functional level. To identify these deficits, we undertook a multi-center eye-tracking study where we recorded 210 sessions from 42 patients using a novel eye-tracking system that was made specifically for free-viewing in the (ICU); each session lasted 10 min and was labeled with the delirium status of the patient using the Confusion Assessment Method in ICU (CAM-ICU). To analyze this data, we formulate the task of visual attention as a hierarchical generative process that yields a probabilistic distribution of the location of the next fixation. This distribution can then be compared to the measured patient fixation producing a correctness score which is tallied compared across delirium status. This analysis demonstrated that the visual processing system of patients suffering from delirium is functionally restricted to a statistically significant degree. This is the first study to explore the potential mechanisms underpinning visual inattention in delirium and suggests a new target of future research into a disease process that affects one in four hospitalized patients with severe short and long-term consequences.
The invention discloses bone fracture nursing medicine. The bone fracture nursing medicine is composed of oral administration medicine and external applying medicine. The oral administration medicine comprises ginseng, prepared rehmannia roots, white peony roots, rhodiola rosea, hawthorn, angelica sinensis, safflower, corydalis tuber, eucommia ulmoides, teasel roots, medicinal cyathula roots, rhizoma smilacis glabrae, caulis spatholobi, hematoxylon and liquorice. The external applying medicine comprises medicinal cyathula roots, teasel roots, safflower, pseudo-ginseng, cortex acanthopanacis, zaocys dhumnade, frankincense and white spirit. According to the medicine compositions, the oral administration medicine nourishes muscles and bones, relaxes tendon, activates collaterals, promotes qi to active blood, nourishes qi and blood and relieves swelling and pain. The external applying medicine activates blood circulation to dissipate stasis, dredges the joint, strengthens the bones and the muscles and relieves swelling and pain. The oral administration medicine and the external applying medicine act together, in this way, the joint function can be rapidly recovered, and the bones can be recovered.
This study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.
To provide swallowable drug delivery device.SOLUTION: An embodiment of the present invention provides swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the gastrointestinal tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other gastrointestinal lumen. A device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. An embodiment of the invention is particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the gastrointestinal tract.SELECTED DRAWING: Figure 1a
A major goal of hearing-device provision is to improve communication in daily life. However, there is still a large gap between the user's daily-life aided listening experience and hearing-aid benefit as assessed with established speech reception measurements in the laboratory and clinical practice. For a more realistic assessment, hearing-aid provision needs to be tested in suitable acoustic environments. In this study, using virtual acoustics, we developed complex acoustic scenarios to measure speech-intelligibility and listening-effort benefit obtained from hearing-aid amplification and signal enhancement strategies. Measurements were conducted using the participants' own devices and a research hearing aid, the Portable Hearing Laboratory (PHL). On the PHL, in addition to amplification, a monaural and a binaural directional filter, as well as a spectral filter were employed. We assessed the benefit from different signal enhancement strategies at the group and the individual level. At the group level, signal enhancement including directional filtering provided a higher hearing-aid benefit in challenging acoustic scenarios in terms of speech intelligibility compared to amplification alone or combined with spectral filtering. However, no difference between monaural and binaural signal enhancement occurred. On an individual level, we found large differences in hearing-aid benefit between participants. While some benefitted from signal-enhancement algorithms, others benefitted from amplification alone, but additional signal enhancement had a detrimental effect. This shows the importance of an individual selection of signal enhancement strategies as a part of the hearing-aid fitting process.
BACKGROUND: The loss of fat-free mass after rapid weight loss following bariatric surgery shows BMI is inadequate for reporting weight loss, emphasizing the need for a more accurate body composition metric. This study assessed changes in fat mass index (FMI), fat-free mass index (FFMI), and dietary intake over 6 months after one-anastomosis gastric bypass (OAGB), Roux-en-Y gastric bypass (RYGB), and sleeve gastrectomy (SG) across age and sex groups.
MATERIALS AND METHODS: This prospective observational study included 151 bariatric surgery candidates. Data on demographics, anthropometric, body composition, and food intake data were collected before and 6 months after surgery. SPSS version 22 was used for analysis, employing ANOVA and t-tests to assess group differences.
RESULTS: Younger patients (≤ 35 years) had higher percent total and excess weight loss (%TWL and %EWL) across all bariatric surgeries, and those undergoing SG experienced more favorable changes in fat-free mass (FFM) and visceral fat compared to other procedures (P = 0.002). Males had higher percent change in fat mass index (%∆ FMI) and visceral fat than females with OAGB and RYGB (P < 0.05). Women undergoing SG and RYGB had a more significant decrease in energy intake compared to OAGB (P < 0.001), and the ≤ 35 and 35-44 age groups demonstrated lower reductions in energy intake following OAGB.
CONCLUSION: Age, sex, and surgery type significantly affect bariatric surgery outcomes. Younger patients achieved greater weight-related improvements, while men undergoing RYGB experienced more substantial fat mass changes than women.
This Cohort C will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants with uncommon EGFR mutations. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
The participants included in this study will be drawn from the Ingenix Normative Health Informatics Database, a proprietary research database containing claims and enrollment data dating back to 1993 for members of a large, geographically diverse US health plan. This study will include cohorts of participants who have claims consistent with a diagnosis of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis and who initiate golimumab, anti-TNF biologics, non-anti-TNF biologics, or systemic non-biological treatments. Participants will be identified by claims bearing codes for dispensed drugs, procedures or diagnoses and followed after the launch of golimumab for up to 8 years. A sample of enrolled health plan members without claims evidence of diagnosis or treatment of Rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis will also be selected. The claims database will be used to estimate the incidence of the primary outcomes of serious infections, tuberculosis (TB) and non-TB mycobacterial infections, malignancies such as lymphoma, and other selected outcomes. No study agents will be administered in this study. All participants will receive standard-of-care treatment as prescribed by their physician
PURPOSE:To provide the title composition of improved hair-dyeing power, capable of dyeing with natural feeling, made up of the first agent containing a sulfite, etc., and a quinoline dye and the second agent containing an iron salt and hydroxyl compound. CONSTITUTION:The objective composition made up of the first agent and the second agent. The first agent can be prepared by formulating (A) 0.1-20wt.% of at least one salt selected from sulfites, bisulfites, thiosulfates and thioglycolates, (B) 0.05-2wt.% of a quinoline dye and (C) an alkali agent. The weight ratio A/B is pref. 1:(0.001-2). The second agent can be prepared by formulating (D) 0.1-20wt.% of an iron salt, (E) 0.1-10wt.% of a hydroxyl compound (both the components D and E being the essential ones) and (F) a water-soluble surfactant and/or reducing agent. After applied, the first agent is left to stand for 20-30min followed by application of the second agent to accomplish hair- dyeing. The quinoline dye is e.g. disodium 2-(2-quinoline)-1,3- indanedionedisulfonate.
There has been substantial evidence from clinical trials to support the rationale of use of thiazide diuretics in patients with essential hypertension. Diuretics may be more effective in reduction of blood pressure in Japanese patients than Caucasian because of higher salt intake. Moreover, given a large number of hypertensive population here, diuretics may be the most cost-effective antihypertensive agent. Japanese physicians, however, tend to avoid diuretics even in elderly hypertensive patients because of much concern over metabolic adverse events including new onset diabetes, which is deemed to increase cardiovascular risk. Although it is unlikely that use of low dose (12.5 mg of HCTZ or less) diuretics is associated with metabolic adverse events when they are given with any other appropriate antihypertensive agents (e.g. Ca antagonist, ACE inhibitor, ARB, K sparing diuretics) other than β-blockers, the researchers have to confirm the safety of low dose diuretics in terms of new onset diabetes in Japanese, who are assumed to be "diabetes prone" based upon thrifty gene hypothesis.
Assumption of 1 vial/day starting from the day after enrollment for 56 days. This supplement contains Collagen, Hyaluronic Acid, Vitamin C, and Manganese.
The invention discloses an extraction separation method of a chromone glycoside compound and application of the chromone glycoside compound in preparation of an analgesic anti-inflammatory medicine. The extraction separation method of the chromone glycoside compound comprises the following steps: 1) chopping a viscum liquiddambaricolum hayata total plant, carrying out cold-soaked extracting with ethanol, carrying out reduced pressure concentration on an extracting solution until no ethanol flavour exists, and extracting by utilizing petroleum ether and EtOAc sequentially, so as to obtain petroleum ether extract and EtOAc extract; and 2) taking the EtOAc extract, and carrying out separation and purification, thus obtaining the chromone glycoside compound. A structure formula of the chromone glycoside compound is described in the specification. The chromone glycoside compound can be applied to preparation of the analgesic anti-inflammatory medicine. A pharmaceutical composition containing the chromone glycoside compound is composed of the chromone glycoside compound and pharmaceutical materials. The chromone monomeric compound is extracted and separated from a viscum liquiddambaricolum hayata natural product and has good application prospect in preparation of the analgesic anti-inflammatory medicine.
BACKGROUND: Textured implants and expanders are associated with an increased risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). As a result, plastic surgeons are utilizing smooth expanders, but many perceive these produce undesirable outcomes including infection, seroma, and lateral displacement.
OBJECTIVES: The aim of this study was to compare clinical outcomes of smooth and textured expanders.
METHODS: Breast reconstruction patients from January 2018 to May 2021 were retrospectively reviewed. Included patients underwent placement of tissue expanders at the time of mastectomy. Primary outcomes included postoperative seroma, infection, malposition, days to final reconstruction, explantation, and the need for capsulorrhaphy.
RESULTS: In total, 233 patients were reviewed, of whom 167 met both inclusion and exclusion criteria. There was no statistically significant difference in poor outcomes comparing smooth and textured expanders. Days to final reconstruction was lower with smooth expanders per breast (P = .0424). The subpectoral group was associated with an increased likelihood of undergoing capsulorrhaphy (P = .004). Prepectoral placement was associated with more seromas (P = .0176) and infections (P = .0245). Demographic factors included older age as a protective factor for undergoing capsulorrhaphy (odds ratio [OR] = 0.962, P = .038), obesity increased the risk of infection (OR = 5.683, P = .0279) and malposition (OR = 6.208, P = .0222), and radiation was associated with malposition (OR = 3.408, P = .0246).
CONCLUSIONS: There was no significant difference in poor outcomes between smooth and textured expanders. Patient demographics and anatomical plane placement had greater effects on infection, seroma, and the need for capsulorrhaphy compared with tissue expander texturing.
<P>PROBLEM TO BE SOLVED: To provide a skin activation agent heated at 30-45°C when brought into contact with the skin and effective for improving the skin activity (activation of metabolism and improvement of aesthetic quality) by the promotion of blood flow while effectively warming the skin and keeping the skin temperature to a level to maximize the cell activation action of the colostrum of mammals.  <P>SOLUTION: The skin activation agent contains the colostrum of a mammal and a polyhydric alcohol and generates heat on the human skin at 30-45°C. The colostrum of mammal is obtained representatively from dairy cattle, however, the colostrum of human, goat, sheep, horse, camel, etc., is also usable. The colostrum of mammals is preferably defatted for improving the storage stability and pulverized by spray drying or freeze drying. The defatting, spray drying and freeze drying process for producing powdery colostrum can be carried out according to conventional method. Any polyhydric alcohol generating hydration heat by contacting with water can be used in the invention and the examples of the alcohol are propylene glycol, glycerol, etc., especially preferably glycerol.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE: To prepare a liposome having uniform size by adding an aq. medium and contact masses having a specified fine diameter to a container having a dry lipid film on the wall and agitating the container to produce multi-lamellar lipid vesicles. CONSTITUTION: One or more kinds of lipids in an org. solvent are introduced into a container to form a thin film of the lipid on the wall of the container and dried. Then, an aq. liquid and contact masses having 50 to 3,000 μm average diameter are added to the container, which is then agitated to form multi- lamellar lipid vesicles encapsulating an aq. soln. having average 150 to 3,000 nm diameter. As for the lipids, phospholipid, sphingolipid, glycolipid and fatty acids are used. As for the contact masses, spherical glass beads having the average diameter selected from 3,000 among μm, 758 μm, 402 μm, 150 to 210 μm and 50 to 100 μm are preferably used.
FIELD: mechanics. ^ SUBSTANCE: invention relates to a sheet characterised by adhesion to textiles and containing a homogenous prepared and sewn matrix formed by one or multiple polymer(s) and having at least a single surface that is disclosed during usage; at least one of the polymers abovementioned is a synthetic polymer having additional functional groups of the first form; the above matrix sewing is done at the expense of some of the above functional groups of the first form while the other functional groups of the first form are free. The sheet is particularly applicable as a textile glue and as a sealing material and is intended for local overlay on the body inner and outer surfaces for medical purposes. The invention additionally relates to sheets containing a support material, 3D products moulded from a material similar to that of the sheet and implantable medical devices coated with such material. ^ EFFECT: sheet is noted for good initial adhesion to textile surface. ^ 18 cl, 7 dwg, 2 tbl, 16 ex